Kazia Therapeutics Limited
Officers & Directors
Bryce Carmine serves as Chairman and Non-Executive Director. He holds a B.Sc. in Biochemistry, Microbiology, and Genetics. Carmine spent 36 years at Eli Lilly & Co., retiring as Executive Vice President and President of Lilly Bio-Medicines, with leadership roles in global pharmaceutical sales, marketing, and product development. He was Chairman and CEO of HaemaLogiX Pty Ltd until December 2023 and has been a director there since January 2024.
Steven Coffey is a Non-Executive Director with a B. Comm and Chartered Accountant (CA) qualification. He is a registered company auditor with over 35 years of experience, a partner at Watkins Coffey Martin, and a consultant to Charternet Chartered Accountants. Coffey has served on boards including Ansarada Group Limited.
Ebru Davidson is a Non-Executive Director holding a BSc, JD (Hons), AGIA, and GAICD. She has been General Counsel for QBiotics Group Limited since 2021 and was a partner at Thomson Geer Lawyers from 2017 to 2021. Davidson has over 14 years of experience in equity capital markets, mergers and acquisitions, corporate transactions, and governance.
Robert Apple is a Non-Executive Director with a B.A. and more than 25 years of pharmaceutical leadership experience. He spent 16 years at Antares Pharma, Inc., serving as Senior Vice President, Chief Financial Officer, Corporate Secretary, and later Chief Executive Officer until its acquisition in 2022. Apple has served on the boards of Antares, InKine Pharmaceutical, PaxMedica Inc., and Kerathin Inc.
John Friend was appointed Chief Executive Officer on 1 May 2023, Managing Director from 1 August 2023 through December 2024, and Interim Chairman of the Board on 11 August 2023. He previously served as Chief Medical Officer until 30 April 2023. Friend holds a B.A. and M.D. and has experience as a physician executive in start-up biotechnology companies and multinational firms.
Kazia Therapeutics Limited currently has 47 employees.
|
